» Authors » Michelangelo Bauwelz Gonzatti

Michelangelo Bauwelz Gonzatti

Explore the profile of Michelangelo Bauwelz Gonzatti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 14
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzatti M, Freire B, Antunes M, de Menezes G, Talbot J, Peron J, et al.
iScience . 2023 Oct; 26(10):107947. PMID: 37841583
Invariant Natural Killer T (iNKT) cell activation by α-galactosylceramide (αGC) potentiates cytotoxic immune responses against tumors. However, αGC-induced liver injury is a limiting factor for iNKT-based immunotherapy. Although adrenergic receptor...
2.
Gonzatti M, Monteiro Junior J, Rocha A, de Oliveira J, Evangelista A, Fonseca F, et al.
Adv Med Sci . 2023 Oct; 68(2):402-408. PMID: 37837799
Purpose: Dipeptidyl peptidase 4 (DPP) inactivates a range of bioactive peptides. The cleavage of insulinotropic peptides and glucagon-like peptide 1 (GLP) by DPP directly influences glucose homeostasis. This study aimed...
3.
Aguiar C, Correa-da-Silva F, Gonzatti M, Angelim M, Pretti M, Davanzo G, et al.
Cell Rep . 2023 Feb; 42(1):112035. PMID: 36848232
Invariant natural killer T (iNKT) cells are a distinct population of lymphocytes characterized by their reactivity to glycolipids presented by CD1d. iNKT cells are found throughout the body, and little...
4.
Freire C, Taunay-Rodrigues A, Gonzatti M, Fonseca F, da Cruz Freire J
Curr Res Microb Sci . 2021 Nov; 2:100042. PMID: 34841333
Nowadays, clinical and scientific interest in antibiotics, as polymyxin, has increased due to the large number of reports of multiresistant Gram-negative bacteria, as . The aim of this study was...
5.
Gonzatti M, Sousa M, Tunissi A, Mortara R, de Oliveira A, Cerize N, et al.
Int J Pharm . 2019 May; 565:123-132. PMID: 31075434
The recognition of α-galactosylceramide (αGC), a high-affinity CD1d antigen, by the invariant Natural Killer T (iNKT) lymphocytes results in potent immunostimulatory responses that have been exploited in advanced cancer patients....